Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Spriano

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma AgentsFilippo Spriano, Elaine Yee Lin Chung, Eugenio Gaudio, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Molecular Cancer Therapeutics|December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica|April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axisAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica|November 2, 2020
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma modelsEugenio Gaudio, Chiara Tarantelli, Filippo Spriano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination TherapyChiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasAlberto J Arribas, Francesca Guidetti, Eleonora Cannas, et al.
Nature Communications|February 3, 2021
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancerTiziano Bernasocchi, Geniver El Tekle, Marco Bolis, et al.
Blood|May 29, 2026
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasAlberto J Arribas, Eleonora Cannas, Giulio Sartori, et al.
Haematologica|June 20, 2024
A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancersFilippo Spriano, Giulio Sartori, Jacopo Sgrignani, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma AgentsFilippo Spriano, Elaine Yee Lin Chung, Eugenio Gaudio, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Molecular Cancer Therapeutics|December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica|April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axisAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica|November 2, 2020
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma modelsEugenio Gaudio, Chiara Tarantelli, Filippo Spriano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination TherapyChiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasAlberto J Arribas, Francesca Guidetti, Eleonora Cannas, et al.
Nature Communications|February 3, 2021
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancerTiziano Bernasocchi, Geniver El Tekle, Marco Bolis, et al.
Blood|May 29, 2026
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomasAlberto J Arribas, Eleonora Cannas, Giulio Sartori, et al.
Haematologica|June 20, 2024
A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancersFilippo Spriano, Giulio Sartori, Jacopo Sgrignani, et al.
Pageof 4